The US Food and Drug Administration’s (FDA) Division of Rheumatology has authorized the clinical development of XBiotech’s Investigational New Drug (IND) Natrunix, a candidate antibody therapy to treat rheumatological diseases. Rheumatological disease, a condition affecting the joints, is diagnosed in about one-third of adults between 45 and 64 years old and half of adults over the age of 65, totaling around 53 million people in the United States. As a drug, Natrunix works by selectively blocking inflammation that affects the joints and is not expected to have serious side effects or cause general immunosuppression, a promising development for the treatment of inflammatory joint diseases such as osteoarthritis and rheumatoid arthritis (RA). Having been approved to launch phase 1 of the study, Natrunix is expected to target a range of rheumatological diseases, conditions which have commonly been treated with steroids to suppress inflammation. XBiotech is a global biosciences company that uses innovative technology for the discovery, development, and commercialization of therapeutic antibodies.
Read more here.
Don’t miss the next article from HealthFirst 100.
Join our mailing list to receive the latest posts from our blog directly in your inbox.